Clinical Trials · NCT05607004
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Atossa Therapeutics, Inc.
- Enrollment
- 87
- Start date
- Feb 2023
- Locations
- 15 sites, United States
- Primary endpoint
- PK Cohort - (Z)-endoxifen steady-state plasma concentrations